Hanmi Pharm, “ZAI Lab will return Chinese license of olmutinib, targeted cancer therapy”

ZAI Lab decided to return the license of ‘olmutinib(HM61713),’ a targeted therapy for cancer, due to the company’s change of new drug development strategy in Chana, and Hanmi Pharm announced on the 29th that Hanmi Pharm had no responsibility of returning the received upfront payment.

In regards to this, “We will make plans to review new clinical study plans which include the Chinese area. We a...